Addex Therapeutics Ltd
ADXN | SIX
Overview
Corporate Details
- ISIN(s):
- CH0029850754 (+2 more)
- LEI:
- 89450068Y9KVP2MQGH86
- Country:
- Switzerland
- Address:
- c/o Addex Pharma SA, Chemin des Aulx 12, 1228 Plan-Les-Ouates
- Sector:
- Health Care
- Industry:
- Pharmaceuticals
Description
Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders. Allosteric modulators offer several potential advantages over conventional non-allosteric molecules and may offer an improved therapeutic approach to conventional "orthosteric" small molecule or biological drugs. Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention. Addex's lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is in a pivotal registration clinical trial for Parkinson’s disease levodopa induced dyskinesia (PD-LID).
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-06-06 02:00 |
Regulatory News Service
Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Multiple…
|
English | 7.4 KB | |
| 2025-06-05 02:00 |
Regulatory News Service
Addex to Present Positive GABAB PAM Chronic Cough Data at the 10th American Cou…
|
English | 6.4 KB | |
| 2025-06-03 02:00 |
General Meeting Notice
Addex Convenes Annual General Meeting 2025
|
English | 6.8 KB | |
| 2025-05-12 02:00 |
Regulatory News Service
Addex Partner Indivior Advances GABAB Positive Allosteric Modulator Program Suc…
|
English | 6.6 KB | |
| 2025-01-08 01:00 |
Regulatory News Service
Addex to Present at the 2025 Swiss Equities Baader Conference
|
English | 5.2 KB | |
| 2024-11-22 01:00 |
Regulatory News Service
Addex Reports Third Quarter 2024 Financial Results and Provides Corporate Update
|
English | 17.7 KB | |
| 2024-11-11 01:00 |
Earnings Release
Addex Provisional 2024 Third Quarter Results Showed Net Loss Compared to Second…
|
English | 7.1 KB | |
| 2024-09-30 02:00 |
Regulatory News Service
Addex Therapeutics Reports 2024 Half Year and Second Quarter Financial Results …
|
English | 17.2 KB | |
| 2024-09-19 02:00 |
Earnings Release
Addex Provisional 2024 Half-Year and Second Quarter Result increased from a Net…
|
English | 7.0 KB | |
| 2024-09-04 02:00 |
Regulatory News Service
Addex to Participate in the H.C. Wainwright 26th Annual Global Investment Confe…
|
English | 5.2 KB | |
| 2024-08-27 02:00 |
Regulatory News Service
Addex and Indivior Select Clinical Candidates from GABAB Positive Allosteric Mo…
|
English | 7.4 KB | |
| 2024-07-22 02:00 |
Regulatory News Service
Addex’s Partner Discontinues ADX71149 development in Epilepsy
|
English | 8.2 KB | |
| 2024-07-15 02:00 |
Regulatory News Service
Addex Presents Positive Results from GABAB PAM Cough Program at the Thirteenth …
|
English | 7.2 KB | |
| 2024-07-12 02:00 |
Regulatory News Service
Addex To Present at the Thirteenth London International Cough Symposium (13th L…
|
English | 5.8 KB | |
| 2024-07-01 02:00 |
Declaration of Voting Results & Voting Rights Announcements
Addex Shareholders Approve All Resolutions at Annual General Meeting
|
English | 6.7 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-11-27 | N/A | Executive member | Buy | None | 301,345.00 CHF |
| 2023-11-27 | N/A | Executive member | Buy | None | 53,760.00 CHF |
| 2023-11-27 | N/A | Executive member | Buy | None | 45,450.00 CHF |
| 2023-11-27 | N/A | Non-Executive member | Buy | None | 44,856.00 CHF |
| 2023-11-27 | N/A | Non-Executive member | Buy | None | 24,423.00 CHF |
| 2023-11-27 | N/A | Executive member | Buy | None | 5,487.00 CHF |
| 2023-11-27 | N/A | Non-Executive member | Buy | None | 3,927.00 CHF |
| 2023-11-27 | N/A | Executive member | Buy | None | 2,150.00 CHF |
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
Cannabotech Ltd. | Israel | CNTC | |
| Canzon Israel Ltd. | Israel | CNZN | ||
|
CATALYST MEDIA GROUP PLC | United Kingdom | CMX | |
|
Celon Pharma S.A. | Poland | CLN | |
|
Chemical Works of Gedeon Richter Plc | Hungary | RICHT | |
|
COSMO Pharmaceuticals N.V. | Netherlands (Kingdom of the) | COPN | |
|
DanCann Pharma A/S | Denmark | DANCAN | |
|
DARWIN AG | Germany | 7V0 | |
|
Dechra Pharmaceuticals PLC | United Kingdom | DPH | |
|
Dermapharm Holding SE | Germany | DMP |